Interesting review of research on the impact of inflammation on the dopamine system as well as a theoretical model and computational method trying to connect it all.
Could be a hypothesis as to why Abilify and dopaminergic agents have some partial efficacy in ME, even if it is temporary (so only a part of the ME symptom story, not for example what are the cause(s) of the chronic inflammation).
Can’t or Won’t? Immunometabolic Constraints on Dopaminergic Drive
Treadway MT et al. Trends Cogn Sci. (2019)
News summary from ScienceDaily:
How chronic inflammation may drive down dopamine and motivation
Could be a hypothesis as to why Abilify and dopaminergic agents have some partial efficacy in ME, even if it is temporary (so only a part of the ME symptom story, not for example what are the cause(s) of the chronic inflammation).
Can’t or Won’t? Immunometabolic Constraints on Dopaminergic Drive
Treadway MT et al. Trends Cogn Sci. (2019)
Inflammatory cytokines have been shown to have a direct effect on mesolimbic dopamine (DA) that is associated with a reduced willingness to expend effort for reward. To date, however, the broader implications of this communication between inflammation and mesolimbic DA have yet to be explored. Here, we suggest that the metabolic demands of chronic low-grade inflammation induce a reduction of striatal DA that in turn leads to a steeper effort-discounting curve because of reduced perceived ability (can’t) versus preference (won’t) for reward. This theoretical framework can inform how the mesolimbic DA system responds to increased immunometabolic demands during chronic inflammation, ultimately contributing to motivational impairments in psychiatric and other medical disorders.
News summary from ScienceDaily:
How chronic inflammation may drive down dopamine and motivation
Last edited: